• Loading stock data...
Slide background

INVESTORS

Zleepax in Brief

Zleepax is a New York-based pharmaceutical company devoted to improving nighttime and daytime quality of life for people with insomnia.

Our patent-pending compound, ZLX-1, has demonstrated efficacy without the unwanted side effect associated with traditional hypnotics, identified as the No. 1 problem with current sleep medication.

IndustryPharmaceuticals
ProductPrescription sleep medication
Product NameZLX-1
InnovationBased on advanced new
beta blockers
Patent ApplicationEP20080758258
Phase II2017
Phase III2019
Projected launch2022
OwnershipPublicly traded company
57% owned by founder and CEO
9,5% owned by company advisors
32.5% owned by minority (<5%)

One digit $ Million to bring Zleepax to Phase III Clinical Testing

As chief executive officer at Blake Insomnia, I am responsible for piloting our company safely towards the launch of our first formulation, ZLX-1.

 

Blake Insomnia Therapeutics Inc. is ready to issue new shares to raise private seed capital, considerably less than average for new chemical entities, because ZLX-1 is based on a well-known, safe agent that is already proven to enhance sleep8.

 

To complete Phase II, Blake Insomnia is ready to issue new shares to raise a one digit USD million amount, considerably less than average for new chemical entities, because ZLX-1 is based on a wellknown, safe agent that is already proven to enhance sleep8.

In addition to overseeing the new share issuance and preparations for clinical testing, I am currently transitioning our organization from its current structure to a more mature organizational form. This includes establishing a fully fledged board of directors, appointing a science advisory board and hiring a project manager.

The ZLX-1 is expected to reach the market via a licensing, sale to or partnership with a larger pharmaceutical company.

CEO

 

Birger Jan Olsen
CEO, Founder & inventor

ZLX-1

Phase I has been accomplished
Phase II
Phase III
Phase IV
 Phase IPhase IIPhase IIIPhase IV
Participants20–10075–300>300>1,000
Estimated Time1 Year1–2 years1–4 years+1 year
ProcessStudies safetyStudies efficacyStudies safety, efficacy and dosing Studies long-term efficacy & cost-effectiveness